| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
69,020,000 |
| Market
Cap: |
106.29(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.6003 - $4.53 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile NGM Biopharmaceuticals is a biopharmaceutical company. Co. has five product candidates in the clinic, three wholly-owned by Co. (NGM707, NGM120 and aldafermin), one being progressed by its collaborator, Merck Sharp & Dohme Corp., or Merck (MK-3655) and one optionable by Merck (NGM621). Co.'s oncology product candidates include NGM707, NGM831, NGM438 and NGM120 and their related compounds. NGM621 was engineered to bind to, and be a long-acting inhibitor of, complement C3 with the treatment goal of reducing disease progression in patients with geographic atrophy, secondary to age-related macular degeneration. MK-3655 isin Phase 2b development for the treatment of nonalcoholic steatohepatitis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
94,704 |
94,704 |
9,606,382 |
| Total Buy Value |
$0 |
$64,854 |
$64,854 |
$87,820,003 |
| Total People Bought |
0 |
4 |
4 |
5 |
| Total Buy Transactions |
0 |
10 |
10 |
130 |
| Total Shares Sold |
0 |
0 |
0 |
85,082 |
| Total Sell Value |
$0 |
$0 |
$0 |
$438,308 |
| Total People Sold |
0 |
0 |
0 |
1 |
| Total Sell Transactions |
0 |
0 |
0 |
1 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Chen Jin-Long |
Chief Scientific Officer |
• • – |
2020-09-01 |
4 |
AS |
$17.62 |
$445,829 |
D/D |
(25,000) |
970,005 |
|
49% |
|
| Svennilson Peter |
Managing Partner |
– – • |
2020-08-28 |
4 |
B |
$17.89 |
$467,555 |
D/D |
26,135 |
1,762,936 |
2.45 |
48% |
|
| Kutzkey Tim |
Managing Partner |
– – • |
2020-08-28 |
4 |
B |
$17.89 |
$467,555 |
D/D |
26,135 |
1,762,936 |
2.45 |
48% |
|
| Svennilson Peter |
Managing Partner |
– – • |
2020-08-27 |
4 |
B |
$17.79 |
$646,827 |
D/D |
36,359 |
1,736,801 |
2.45 |
56% |
|
| Kutzkey Tim |
Managing Partner |
– – • |
2020-08-27 |
4 |
B |
$17.79 |
$646,827 |
D/D |
36,359 |
1,736,801 |
2.45 |
56% |
|
| Svennilson Peter |
General Partner |
– – • |
2020-08-25 |
4 |
B |
$18.00 |
$1,800 |
D/D |
100 |
1,700,442 |
2.37 |
50% |
|
| Kutzkey Tim |
Managing Partner |
– – • |
2020-08-25 |
4 |
B |
$18.00 |
$1,800 |
D/D |
100 |
1,700,442 |
2.37 |
50% |
|
| Svennilson Peter |
General Partner |
– – • |
2020-08-24 |
4 |
B |
$17.96 |
$197,991 |
D/D |
11,024 |
1,700,342 |
2.45 |
52% |
|
| Kutzkey Tim |
Managing Partner |
– – • |
2020-08-24 |
4 |
B |
$17.96 |
$197,991 |
D/D |
11,024 |
1,700,342 |
2.45 |
52% |
|
| Svennilson Peter |
General Partner |
– – • |
2020-08-21 |
4 |
B |
$17.97 |
$131,558 |
D/D |
7,321 |
1,689,318 |
2.45 |
54% |
|
| Kutzkey Tim |
Managing Partner |
– – • |
2020-08-21 |
4 |
B |
$17.97 |
$131,558 |
D/D |
7,321 |
1,689,318 |
2.45 |
54% |
|
| Svennilson Peter |
General Partner |
– – • |
2020-08-17 |
4 |
B |
$17.89 |
$114,943 |
D/D |
6,425 |
1,681,997 |
2.45 |
76% |
|
| Kutzkey Tim |
Managing Partner |
– – • |
2020-08-17 |
4 |
B |
$17.89 |
$114,943 |
D/D |
6,425 |
1,681,997 |
2.45 |
76% |
|
| Svennilson Peter |
General Partner |
– – • |
2020-08-14 |
4 |
B |
$17.49 |
$664,498 |
D/D |
37,993 |
1,675,572 |
2.45 |
81% |
|
| Kutzkey Tim |
Managing Partner |
– – • |
2020-08-14 |
4 |
B |
$17.49 |
$664,498 |
D/D |
37,993 |
1,675,572 |
2.45 |
81% |
|
| Svennilson Peter |
General Partner |
– – • |
2020-08-13 |
4 |
B |
$17.89 |
$355,922 |
D/D |
19,895 |
1,637,579 |
2.45 |
74% |
|
| Kutzkey Tim |
Managing Partner |
– – • |
2020-08-13 |
4 |
B |
$17.89 |
$355,922 |
D/D |
19,895 |
1,637,579 |
2.45 |
74% |
|
| Chen Jin-Long |
Chief Scientific Officer |
• • – |
2020-08-10 |
4 |
AS |
$19.02 |
$475,500 |
D/D |
(25,000) |
995,005 |
|
57% |
|
| Column Group Ii Gp, Lp |
General Partner |
– – • |
2020-07-30 |
4 |
B |
$17.99 |
$13,169 |
D/D |
732 |
1,617,684 |
2.37 |
40% |
|
| Svennilson Peter |
General Partner |
– – • |
2020-07-30 |
4 |
B |
$17.99 |
$13,169 |
D/D |
732 |
1,617,684 |
2.37 |
40% |
|
| Column Group Ii Gp, Lp |
General Partner |
– – • |
2020-07-28 |
4 |
B |
$17.99 |
$73,849 |
D/D |
4,105 |
1,616,952 |
2.45 |
39% |
|
| Svennilson Peter |
General Partner |
– – • |
2020-07-28 |
4 |
B |
$17.99 |
$73,849 |
D/D |
4,105 |
1,616,952 |
2.45 |
39% |
|
| Svennilson Peter |
General Partner |
– – • |
2020-07-27 |
4 |
B |
$17.99 |
$68,974 |
D/D |
3,834 |
1,612,847 |
2.45 |
36% |
|
| Column Group Ii Gp, Lp |
General Partner |
– – • |
2020-07-27 |
4 |
B |
$17.99 |
$68,974 |
D/D |
3,834 |
1,612,847 |
2.45 |
36% |
|
| Svennilson Peter |
General Partner |
– – • |
2020-07-24 |
4 |
B |
$17.93 |
$1,232,670 |
D/D |
68,749 |
1,609,013 |
2.45 |
39% |
|
107 Records found
|
|
Page 4 of 5 |
|
|
